Work

Correction to Lancet Haematol 2026; 13: e74–85

Year: 2026

Type: erratum

Abstract: Heitmann JS, Maringer Y, Jung S, et al. Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study. Lancet Haematology 2026; 13: e74–85—In this Article, Ariane Metzger's surname and Melissa Zwick's degree qualification were amended. Mark Polster's affiliations should have been “Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany”, “Department of Peptide-based Immunotherapy, University and University Hospital of Tübingen, Tübingen, Germany”, and “Department of Computer Science, University of Tübingen, Tübingen, Germany”.

Source: The Lancet Haematology

DOI: 10.1016/s2352-3026(26)00012-8

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $7,280

Funders: Wilhelm Sander-Stiftung, Deutsche Forschungsgemeinschaft, Eberhard Karls Universität Tübingen, Bundesministerium für Bildung und Forschung, Deutsche Krebshilfe, Deutschen Konsortium für Translationale Krebsforschung, Schleswig-Holstein

Awards: G1733652078, G2853181762, G3807383156, G392122573, G3988570459, G5677642423

OpenAlex ID: W7127564031

Cites:

Cited by:

Related to: